Benjamin N. Rome, M.D.
Dr. Rome is general internist and health policy researcher at Harvard Medical School. He is a faculty member in the Division of Pharmacology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital. He received his undergraduate degree in community health from Brown University, his medical degree from Harvard Medical School, trained in internal medicine at Brigham and Women's Hospital, and is currently an MPH candidate at the Harvard T.H. Chan School of Public Health. Dr. Rome is a practicing primary care physician at the Phyllis Jen Center for Primary Care at Brigham and Women's Hospital.
Within the Division, Dr. Rome works within the Program On Regulation, Therapeutics, And Law (PORTAL) to study the evaluation, regulation, cost, and use of prescription drugs in the United States. His research interests include how drug prices affect patient adherence and clinical outcomes, value-based drug pricing, and policies to make medications more affordable to patients. His work has been has published in the New England Journal of Medicine, JAMA, Health Affairs, and JAMA Internal Medicine. His research has also been featured in a Congressional report about rising prescription drug prices and he has testified in front of the US House of Representatives about evidence-based drug approval during the Covid-19 pandemic.
Within the Division, Dr. Rome works within the Program On Regulation, Therapeutics, And Law (PORTAL) to study the evaluation, regulation, cost, and use of prescription drugs in the United States. His research interests include how drug prices affect patient adherence and clinical outcomes, value-based drug pricing, and policies to make medications more affordable to patients. His work has been has published in the New England Journal of Medicine, JAMA, Health Affairs, and JAMA Internal Medicine. His research has also been featured in a Congressional report about rising prescription drug prices and he has testified in front of the US House of Representatives about evidence-based drug approval during the Covid-19 pandemic.
Back to PORTAL Research Team
